MEDICREA Reports Third Quarter 2020 Sales
08 Ottobre 2020 - 10:34PM
Business Wire
- Q3 Sales Growth: +4% in the USA and +11% in France vs Q3
2019
- Strong Demand in UNiD® Activity in the USA for September:
+49% vs 2019
- 6,450 UNiD™ Personalized Surgeries Performed on a Cumulatve
Basis as of September 30, 2020
The MEDICREA® Group (Euronext Growth Paris: FR0004178572 – ALMED
; OTCQX Best Market –MRNTF), pioneering the transformation of
spinal surgery through Artificial Intelligence, predictive modeling
and patient specific implants with its UNiD™ ASI (Adaptive Spine
Intelligence) proprietary software platform, services and
technologies, publishes sales for the third quarter of 2020.
(€ millions)
YTD September 2019
YTD September 2020
Variation
USA
Rest of the world
Total Sales
Including Q3
13.7
10.6
24.3
8.2
12.6
8.7
21.3
8.1
-8%
-18%
-12%
-2%
Sales for the third quarter amounted to €8.1 million, a slight
decrease of 2% compared to Q3 2019. U.S. sales grew by 4% in dollar
volume over the quarter and revenue in France increased by 11%
compared to the same quarter last year, boosted by the resumption
of spine surgeries following the lifting of containment measures.
However, the Group's overall performance is negatively impacted by
the decline in export sales outside of subsidiaries, where
distributors are being hit hard, depending on their location, by
sharp declines in activity due to the effects of the health crisis
and the measures taken to deal with it.
Cumulative sales at the end of September 2020 reached €21.3
million, down 12% compared to the same period in 2019 due to the
COVID-19 pandemic and the postponement of many surgeries.
UNiD ASI™, the strategic activity of preoperative surgical
planning and patient-specific implant design, is once again growing
significantly, with a monthly record of 234 personalized surgeries
reached in September 2020, driven by the United States where the
number of UNiD® surgeries increased by +49% in September, +31% in
the third quarter and +23% year-to-date at the end of
September.
« The strong growth of UNiD® personalized surgeries in a general
context of declining sales and reduction in the number of
procedures since March due to the global health crisis we are going
through, demonstrates the relevance of the solution and the
technological platform we have developed for surgeons and patients.
The upcoming integration of MEDICREA® within the MEDTRONIC Group
will enable the technology to be deployed on a very large scale,
making it a global standard in spinal surgery, offering a solution
that integrates MEDICREA®'s Artificial Intelligence-driven surgical
planning and patient-specific implants with MEDTRONIC's robotic
assisted surgery » commented Denys Sournac, President and CEO of
Medicrea.
As a reminder, on October 1st, the French Markets Authority
(AMF) announced that the tender offer for the shares of MEDICREA®
by MEDTRONIC would be opened from October 2nd, 2020 to November
5th, 2020.
Next publication: 2020 Third Quarter results: November
19th, 2020 after market
About MEDICREA® (www.medicrea.com)
Through the lens of predictive medicine, MEDICREA® leverages its
proprietary software analysis tools with big data and machine
learning technologies supported by an expansive collection of
clinical and scientific data. The Company is well-placed to
streamline the efficiency of spinal care, reduce procedural
complications and limit time spent in the operating room.
Operating in a $10 billion marketplace, MEDICREA® is a Small and
Medium sized Enterprise (SME) with 175 employees worldwide, which
includes 35 who are based in the U.S. The Company has an
ultra-modern manufacturing facility in Lyon, France housing the
development and production of 3D-printed titanium patient-specific
implants.
For further information, please visit: medicrea.com.
Connect with MEDICREA® FACEBOOK |
INSTAGRAM | TWITTER | WEBSITE | YOUTUBE
MEDICREA® is listed on EURONEXT Growth Paris
EnterNext PEA PME 150 Index ISIN: FR 0004178572 Ticker: ALMED LEI:
969500BR1CPTYMTJBA37
MEDICREA® is traded on OTCQX Best Market
Ticker: MRNTF
View source
version on businesswire.com: https://www.businesswire.com/news/home/20201008006023/en/
MEDICREA® Denys SOURNAC Founder, Chairman and CEO
dsournac@medicrea.com
Fabrice KILFIGER Chief Financial Officer fkilfiger@medicrea.com
Tel: +33 (0)4 72 01 87 87